Wells Fargo’s Edwards Lifesciences EW Stock Holding History

Wells Fargo’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$1.56M	–	7176
2025 Q2	$1.56M	Buy	+20,000	New	+$1.49M	﹤0.01%	3400
2021 Q3	–	Sell	-1,200	Closed	-$124K	–	7094
2021 Q2	$124K	Hold	1,200	–	–	﹤0.01%	5217
2021 Q1	$100K	Buy	+1,200	New	+$101K	﹤0.01%	5484
2018 Q3	–	Sell	-1,200	Closed	-$2K	–	6443
2018 Q2	$2K	Buy	+1,200	New	+$56K	﹤0.01%	6182
2017 Q1	–	Sell	-177,300	Closed	-$18K	–	6355
2016 Q4	$18K	Buy	+177,300	New	+$5.74M	﹤0.01%	5655
2015 Q1	–	Sell	-52,800	Closed	-$38K	–	6221
2014 Q4	$38K	Buy	+52,800	New	+$1.06M	﹤0.01%	5121
2013 Q4	–	Sell	-6,000	Closed	-$5K	–	5782
2013 Q3	$5K	Buy	+6,000	New	+$70.2K	﹤0.01%	5275

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wells Fargo's EW Position: Q1 2026 in Review

Wells Fargo reduced its Edwards Lifesciences (EW) stake by 0.05% in Q1 2026, selling an estimated $47.9K and leaving 1,081,271 shares worth $86.6M. The position accounts for 0.02% of the portfolio, ranked #691.

Wells Fargo first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $483M in Q2 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Wells Fargo held 1,081,271 shares of Edwards Lifesciences worth $86.6M as of Q1 2026.
Wells Fargo sold 581 Edwards Lifesciences shares in Q1 2026, an estimated $47.9K.
Edwards Lifesciences made up 0.02% of Wells Fargo's portfolio in Q1 2026, its #691 holding.
Wells Fargo first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's Edwards Lifesciences position peaked at $483M in Q2 2021.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.